**Core Concept:**
Advanced epithelial ovarian cancer is a type of gynecological cancer that requires specific treatment strategies. After debulking surgery, the primary goal of adjuvant therapy is to eradicate any remaining microscopic disease and improve survival rates.

**Why the Correct Answer is Right:**
For a patient with advanced epithelial ovarian cancer post-surgery, platinum-based chemotherapy is a standard adjuvant therapy. In this case, paclitaxel (Taxol) and cisplatin (CP) are the most commonly used combination. These drugs target and destroy cancer cells, while minimizing damage to healthy cells. This combination is known as CP regimen.

**Why Each Wrong Option is Incorrect:**
A. Chemotherapy alone (Option A) may not provide sufficient efficacy for advanced ovarian cancer.
B. Radiation therapy (Option B) is not the primary treatment for ovarian cancer and is usually used for localized disease.
C. Monotherapy with a single drug (Option C) is less effective compared to the combination of drugs like CP regimen.
D. Targeted therapy (Option D) is usually reserved for specific molecular subtypes of ovarian cancer and may not be relevant for the given case.

**Clinical Pearl / High-Yield Fact:**
Standard care for advanced epithelial ovarian cancer after surgery includes a combination of cisplatin (or carboplatin) and paclitaxel (Taxol) chemotherapy. This CP regimen improves patient survival and response rate compared to monotherapy or other regimens.

In this case, the correct answer is **D** (Cisplatin and Paclitaxel), as it represents the recommended adjuvant therapy for advanced epithelial ovarian cancer post-surgery.